Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, Array Genomics to Co-Develop CGH Diagnostics

NEW YORK, March 13 (GenomeWeb News) - CombiMatrix Molecular Diagnostics, a subsidiary of Acacia Research's CombiMatrix group, said today that it has signed an agreement with Paris-based Array Genomics to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation.


CombiMatrix Molecular Diagnostics will manufacture the arrays in the US, and Array Genomics will distribute them in Europe.


The arrays are expected to begin generating revenue for both companies "within the next several weeks," CMDX said in a statement.


The array-based CGH tests will reduce the time associated with the analysis of chromosomal imbalances compared to conventional cytogenetic approaches while increasing the detection resolution, CMDX said.


Matt Watson, CEO of CMDX, said in a statement that the company will also offer molecular diagnostic testing services based on CGH and gene expression profiling at its Irvine, Calif.-based clinical laboratory, and that it will also file "a number" of its tests with the US Food and Drug Administration for approval to market them within the US as in vitro diagnostics.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.